These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Lau WY; Lai EC; Leung TW; Yu SC Ann Surg; 2008 Jan; 247(1):43-8. PubMed ID: 18156922 [TBL] [Abstract][Full Text] [Related]
5. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Raoul JL; Guyader D; Bretagne JF; Heautot JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M Hepatology; 1997 Nov; 26(5):1156-61. PubMed ID: 9362356 [TBL] [Abstract][Full Text] [Related]
6. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599 [TBL] [Abstract][Full Text] [Related]
7. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. Leung WT; Lau WY; Ho S; Chan M; Leung N; Lin J; Ho KC; Metreweli C; Johnson PJ; Li AK J Nucl Med; 1994 Aug; 35(8):1313-8. PubMed ID: 7519259 [TBL] [Abstract][Full Text] [Related]
8. 131-iodine Lipiodol therapy in hepatocellular carcinoma. Raoul JL; Boucher E; Roland V; Garin E Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):348-55. PubMed ID: 19521315 [TBL] [Abstract][Full Text] [Related]
9. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257 [TBL] [Abstract][Full Text] [Related]
10. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Brans B; Van Laere K; Gemmel F; Defreyne L; Vanlangenhove P; Troisi R; Van Vlierberghe H; Colle I; De Hemptinne B; Dierckx RA Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):928-32. PubMed ID: 12111134 [TBL] [Abstract][Full Text] [Related]
17. Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative (131)I-lipiodol therapy. Brans B; Lambert B; De Beule E; De Winter F; Van Belle S; Van Vlierberghe H; de Hemptinne B; Dierckx RA Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1374-9. PubMed ID: 12271421 [TBL] [Abstract][Full Text] [Related]
18. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589 [TBL] [Abstract][Full Text] [Related]
19. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035 [TBL] [Abstract][Full Text] [Related]
20. Therapy of hepatocellular carcinoma with 131I-lipiodol: patient dosimetry. Risse JH; Pauleit D; Palmedo H; Bender H; Bucerius J; Ezziddin S; Klein V; Grünwald F; Biersack HJ; Reichmann K Nuklearmedizin; 2007; 46(5):192-7. PubMed ID: 17938753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]